Symmetry Partners’s West Pharmaceutical WST Stock Holding History

Symmetry Partners’s Portfolio WST Stock Details WST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-563	Closed	-$223K	–	551
2024 Q1	$223K	Buy	+563	New	+$208K	0.02%	508
2023 Q4	–	Sell	-563	Closed	-$211K	–	560
2023 Q3	$211K	Sell	563 -158	-22%	-$61.1K	0.01%	508
2023 Q2	$276K	Hold	721	–	–	0.01%	486
2023 Q1	$250K	Sell	721 -1,071	-60%	-$313K	0.01%	486
2022 Q4	$422K	Sell	1,792 -1,271	-41%	-$301K	0.03%	377
2022 Q3	$754K	Hold	3,063	–	–	0.05%	217
2022 Q2	$926K	Hold	3,063	–	–	0.06%	183
2022 Q1	$1.26M	Hold	3,063	–	–	0.08%	159
2021 Q4	$1.44M	Hold	3,063	–	–	0.09%	142
2021 Q3	$1.27M	Hold	3,063	–	–	0.08%	165
2021 Q2	$1.1M	Hold	3,063	–	–	0.07%	206
2021 Q1	$863K	Sell	3,063 -11	-0.4%	-$3.15K	0.06%	236
2020 Q4	$871K	Buy	3,074 +3	+0.1%	+$842	0.07%	215
2020 Q3	$844K	Buy	3,071 +729	+31%	+$193K	0.07%	202
2020 Q2	$532K	Buy	2,342 +263	+13%	+$51.7K	0.07%	136
2020 Q1	$317K	Buy	+2,079	New	+$320K	0.07%	195

Other funds holding WST

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

APG Asset Management Amsterdam, Netherlands $40.7B AUM 39.97% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $64.6B AUM 18.98% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Symmetry Partners's WST Position: Q2 2024 in Review

Symmetry Partners sold out of West Pharmaceutical (WST) in Q2 2024, closing a stake of 563 shares — an estimated $223K sold.

Symmetry Partners first reported a position in WST in Q1 2020 and held it in 16 quarters. The position peaked at $1.44M in Q4 2021. 777 funds tracked by Wall St. Rank hold WST as of Q2 2024.

Symmetry Partners reported no remaining West Pharmaceutical position as of Q2 2024 after selling out during the quarter.
Symmetry Partners sold 563 West Pharmaceutical shares in Q2 2024, an estimated $223K.
Symmetry Partners first reported a position in West Pharmaceutical in Q1 2020 and held it in 16 quarters.
Symmetry Partners's West Pharmaceutical position peaked at $1.44M in Q4 2021.
777 funds tracked by Wall St. Rank held West Pharmaceutical as of Q2 2024.

Based on Symmetry Partners's 13F filing for Q2 2024, filed 11 Jul 2024.